{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:53:24Z","timestamp":1791899604704,"version":"4.3.4"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Cardiotoxicity related to osimertinib, including cardiac failure, QT prolongation, and atrial fibrillation, has been reported as an extremely rare incidence in patients with advanced non-small cell lung cancer (NSCLC). However, little is known about the occurrence of osimertinib-induced cardiomyopathy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 76-year old woman was treated with afatinib (40\u200amg\/day) as the 1st line treatment due to recurrence after surgical resection for pulmonary adenocarcinoma. However, she experienced recurrence with positive T790\u200aM, and osimertinib (80\u200amg\/day) was administered as the 2nd line therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Four months after osimertinib initiation, she complained of fever and progressive dyspnea, and a diagnostic endomyocardial biopsy confirmed non-specific cardiomyopathy, indicating osimertinib-induced cardiomyopathy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions and outcomes:<\/jats:title>\n            <jats:p>She was treated with furosemide, carvedilol, and enalapril, and her cardiac function, her symptoms, and condition improved 3 weeks after the withdrawal of osimertinib.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Physicians should be alert of the cardiomyopathy-causing potential of osimertinib in advanced NSCLC patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000022301","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T18:19:07Z","timestamp":1600971547000},"page":"e22301","source":"Crossref","is-referenced-by-count":20,"title":["Osimertinib induced cardiomyopathy"],"prefix":"10.1097","volume":"99","author":[{"given":"Shun","family":"Shinomiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichi","family":"Kaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kagamu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jtho.2017.05.016","article-title":"Cardiac dysfunction caused by osimertinib","volume":"10","author":"Oyakawa","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.2169\/internalmedicine.8344-16","article-title":"Congestive heart failure during osimertinib treatment for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC)","volume":"56","author":"Watanabe","year":"2017","journal-title":"Intern Med"},{"key":"R4-20230915","first-page":"52","article-title":"Osimertinib-induced cardiac dysfunction in EGFR-mutated lung cancer: a case series of five patients","volume":"6","author":"Reale","year":"2018","journal-title":"Am J Cancer Case Reports"},{"key":"R5-20230915","first-page":"172","article-title":"Osimertinib induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS)","volume":"1","author":"Anad","year":"2019","journal-title":"JACC Cardiooncology"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"R7-20230915","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2019.11.029","article-title":"Occurrence of ventricular fibrillation in a patient with lung cancer receiving osimertinib","author":"Kaira","year":"2020","journal-title":"J Thorac Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:00:52Z","timestamp":1694822452000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022301"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":7,"journal-issue":{"issue":"39","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000022301","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]}}}